Clinical trials
Exudative Age-Related Macular Degeneration clinical trials
Below are recruiting exudative age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 25 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Phoenix, ArizonaAges 55 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Phoenix, ArizonaAges 50 years+ - NCT06351605Recruiting
Light therapy study for dry age-related macular degeneration
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
OsloAges Any age - NCT07005323Recruiting
New treatment for resistant wet AMD
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
Ube, YmaguchiAges 50–85 - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+ - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Phoenix, ArizonaAges 50 years+ - NCT04292080RecruitingPhase 2
Tecfidera trial to slow worsening geographic atrophy
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
Créteil, Val De MarneAges 55–85 - NCT04504123RecruitingPhase 2
Doxycycline eye treatment for persistent wet macular degeneration fluid
This trial tests whether an “MMP-9 inhibitor” medicine given as doxycycline (a tetracycline-type antibiotic) can reduce persistent leaking and fluid in wet age-related macular degeneration. It may help people whose wet AMD is not fully controlled even after several anti-VEGF injections.
Iowa City, IowaAges 50–99 - NCT04663750RecruitingPhase 3
Surgery to treat bleeding under the retina in wet macular degeneration
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
BonnAges 50–120 - NCT05438732Recruiting
Test of an implanted eye device plus vision training for AMD
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Loma Linda, CaliforniaAges 65 years+ - NCT05959005Recruiting
Tracking early macular atrophy changes in the eye
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Salt Lake City, UtahAges 50 years+ - NCT06271330Recruiting
Switching older injections to faricimab for wet AMD
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
Nantes, NantesAges 18 years+ - NCT06355830Recruiting
A study of intermediate age-related macular degeneration
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
LisbonAges 55–95 - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT06906003Recruiting
Vision rehab and depression in age-related macular degeneration
This trial tests whether visual rehabilitation can help improve both vision and mood in people with advanced dry age-related macular degeneration. It aims to understand the link between vision loss and depression.
Rome, ItalyAges 55 years+ - NCT07004361Recruiting
Ethics of gene therapy for wet AMD
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Nantes, NantesAges 18 years+ - NCT07235527Recruiting
Aflibercept biosimilar for wet age-related macular degeneration
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Istanbul, şişliAges 45–90 - NCT07249216Recruiting
Eye fluid study for wet AMD treatment response
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
SingaporeAges 50 years+
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for exudative age-related macular degeneration?
- Yes. Clin2 currently lists 25 recruiting exudative age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a exudative age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a exudative age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.